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Summary
Strategically mutated neoceptors, e.g., with anionic
residues in TMs 3 and 7 intended for pairing with pos-
itively charged amine-modified nucleosides, were de-
rived from the antiinflammatory A2A adenosine recep-
tor (AR). Adenosine derivatives functionalized at the
5, 2, and N6 positions were synthesized. The T88D
mutation selectively enhanced the binding of the chain-
length-optimized 5-(2-aminoethyl)uronamide but not
5-(2-hydroxyethyl)uronamide, suggesting a critical
role of the positively charged amine. Combination of
this modification with the N6-(2-methylbenzyl) group
enhanced affinity at the Q89D- and N181D- but not
the T88D-A2AAR. Amino groups placed near the 2- or
N6-position only slightly affected the binding to mu-
tant receptors. The 5-hydrazide MRS3412 was 670-
and 161-fold enhanced, in binding and functionally,
respectively, at the Q89D-A2AAR compared to the
wild-type. Thus, we identified and modeled pairs of
A2AAR-derived neoceptor-neoligand, which are phar-
macologically orthogonal with respect to the native
species.
Introduction
The clinical use of adenosine agonists as cytoprotec-
tive agents [1] has been limited by the widespread oc-
currence of adenosine receptors (ARs), thus leading to
undesirable side effects of exogenously administered
adenosine derivatives. For example, experimental A1AR
agonists developed for the treatment of cerebral isch-
emia [2, 3] also tended to cause a bradycardiac effect
through the same subtype of ARs present in the nodal
conduction system of the heart. Compounds intro-
duced as A2AAR agonists for the treatment of inflamma-
tory conditions via action on immune cells [4–6] are at
risk for also causing hypotension through vascular
A2AARs. Prodrug schemes for overcoming the problem
of actions of adenosine agonists in multiple tissues
[7, 8] have not yet proven fruitful.*Correspondence: kajacobs@helix.nih.govIn order to overcome this inherent nonselectivity of
activating the ARs and other native G protein-coupled
receptors (GPCRs), we have introduced the concept of
neoceptors [9, 10], a means of mutating GPCRs for
eventual application to tissue-targeted gene therapy.
By this strategy, the putative ligand binding site of a
GPCR is reengineered with the aid of molecular model-
ing for unique activation by synthetic, small molecular
agonists (neoligands) built to have a structural comple-
mentarity to the altered binding site. The synthetic ago-
nist would be administered to activate exclusively the
engineered receptor, i.e., neoceptor. The feasibility of
neoceptors has been demonstrated for antiinflamma-
tory A2A and cardioprotective A3ARs [4, 5, 11]. Certain
positively charged amine-modified nucleosides have
demonstrated enhanced affinity at these ARs that had
been strategically mutated with anionic residues. These
mutant receptors retained the ability to activate the
usual second messenger systems. Specifically, amino
groups introduced in the ribose moiety of adenosine
have been found to interact favorably with receptors
modified in the putative ribose binding regions associ-
ated with TMs (transmembrane helical domains) 3 and
7 [9, 10]. Rhodopsin-based molecular modeling of the
receptors (residue identifiers of format X.YZ in paren-
theses refer to the TM X and residue YZ with respect
to a highly conserved amino acid in each TM numbered
50) indicated that hydrophilic residues T (3.36) and H
(7.43) were in proximity to the ribose moiety. 5#-(2-ami-
noethyl)uronamidoadenosine (MRS 3366 1; Figure 1)
displayed selective enhancement of affinity at the T88D
(3.36) mutant A2AAR, at which the standard AR agonists
were poorly recognized [10]. At the H272E (7.43) mutant
A3AR, the 3#-amino-3#-deoxy derivative of adenosine
2 displayed selective affinity enhancement [9]. Amino
groups placed at other positions on the nucleosides
did not enhance the receptor binding. Amino groups
placed close to the nucleoside pharmacophore gen-
erally tended to reduce affinity of agonists at the wild-
type (WT) ARs, while certain amine substitutions selec-
tively enhanced binding affinity at mutant ARs.
In the present study, we have expanded the range of
positions for concerted ligand derivatization and muta-
tion of the human A2AAR. New mutant A2AARs have
been expressed in COS-7 cells and initially examined
using the prototypical nonselective AR agonist NECA 3
and antagonist CGS15943 4. We have systematically
varied the chain length of the 5#-substituents found to
interact putatively with the carboxylate group of T88D
[10]. Furthermore, at the 2 and N6 positions we have
incorporated substitutions [12–14], the effects of which
on AR affinity have already been characterized. Thus,
we are assembling SAR patterns for mutant A2AARs in
an effort to achieve selective matching of neoceptor-
neoligand pairs.
Other similar approaches have been reported for the
orthogonal mutation of receptors and enzymes to re-
cognize unnatural and structurally modified ligands and
substrates [15–19]. Conklin and coworkers have intro-
duced RASSLs (receptors activated solely by synthetic
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wFigure 1. Structures of Nonselective Adenosine Receptor Ligands
(3, 4) and Several Amine Derivatives (1, 2) Previously Studied at p
A2AAR Neoceptors d
t
sligands) and demonstrated this approach for nonpep-
Gtide opiate and other ligands. Shokat and coworkers
c[16, 20] have mutated kinases to accept structurally
(modified inhibitors for use as mechanistic probes.
lSchreiber and coworkers [17] have utilized uniquely
amatched proteins and ligands. By the “bump and hole”
yapproach, a sterically enlarged ligand is designed to fit
Binto a side-chain-truncated protein. The laboratories of
pKatzenellenbogen [18] and Koh [19] have matched mu-
rtant steroid and other hormone receptors with recipro-
ccally altered ligands. In several cases, X-ray crystallo-
mgraphic data are available to guide the design of the
mligands. For nearly all of the GPCRs, such data are lack-
ing, and homology modeling guided by site-directed
tmutagenesis is the principal means of gaining struc-
atural insights.
N
aResults
p
uDesign and Synthesis of Neoligands
tVarious adenosine analogs functionalized at the 5#, 2,
land N6 positions were prepared as potential neoligands
a(Table 1). The modifications included the addition of
damino and various H-bonding groups to both 9-ribo-
side-5#-uronamido 3–15 and 9-riboside 17–19 deriva-
tives. Certain 5#-uronamido derivatives of adenosine, A
Mnotably NECA 3, are known to display enhanced affinity
at the A2AAR. Metrifudil 16, an adenosine agonist that w
twas studied in humans [21], and its 5#-uronamide deriv-
atives 12–15 were included due to the nonselective en- d
phancement by the N6-(2-methylbenzyl) group of affinity
at the ARs. pSynthetic methods for the adenosine analogs are
hown in Figures 2 and 3. A N6-(2-aminoethyl) deriva-
ive 5 was synthesized (Figure 2A) from the protected
-chloro 5#-uronamide precursor 20 [22].
In the first step of the synthesis of the N6-guanidino
erivative 6 of NECA, the readily accessible 6-chloro-
-β-D-ribofuranosyl-9H-purine [23] was converted into
ts 2#,3#-O-isopropylidene derivative [24] 21 (Figure 2B).
he guanidinolysis of the 2#,3#-O-isopropylidene de-
ivative 21 in the presence of DABCO afforded 24 con-
aminated with byproducts; therefore the tert-butyl-
imethylsilyl group (TBDMS) was used to protect the
#-hydroxyl function in intermediate 22 [25]. The subse-
uent guanidinolysis of 22 afforded in good yield 23,
hich was then deprotected on treatment with tetrabu-
ylammonium fluoride solution in tetrahydrofuran. Sub-
equent oxidation of the 5#-OH group with Ru(OH)Cl3
nd NaIO4 afforded the carboxylic acid 25. However, to
void contamination by colloidal metallic Ru, the oxida-
ion was performed with KMnO4 in aqueous KOH. Sub-
equent deprotection of the isopropylidene group by
cid hydrolysis in diluted aqueous H2SO4 gave 26. A
ixed anhydride derived from acid 26 was treated
ithout isolation with ethylamine in MeOH to give the
esired 9-[N-ethyl(β-D-ribofuranosyluronamide)] 6-gua-
idinopurine 6 in a satisfactory yield.
Various 9-riboside-5#-uronamido derivatives 1, 7–11
ere prepared as shown in Figure 3A. The 2#,3#-isopro-
ylidene-protected derivative of adenosine 27 was oxi-
ized using chromium trioxide in acetic acid to provide
he carboxylic acid 28. Amide derivatives 1, 7–11 were
ynthesized by similar methods to those described by
allo-Rodriguez et al. [22]. Initially, we attempted to
ouple 28 and the appropriate amines using 1-[3-
dimethylamino)propyl]-3-ethylcarbodiimide; however,
ow yields were obtained. Aminolysis of ester 29 with
n amines or hydrazine (in the case of 7) improved
ields. In the case of compounds 1, 8–11, a mono-N-
oc-protected diamine was used in this reaction. The
rotecting groups (isopropylidene and N-Boc) were
emoved under mild acidic conditions. The resulting nu-
leosides were purified by ion-exchange column chro-
atography or reverse-phase silica gel column chro-
atography, and their purity was confirmed by HPLC.
The N6-(2-methylbenzyl) derivatives 12–15 were syn-
hesized as shown in Figure 3B by the Dimroth re-
rrangement. The intermediate 32 was alkylated at the
1 position by 2-methylbenzyl bromide, which re-
rranged to the N6 position under basic conditions to
rovide 41–44. Deprotection and purification proced-
res were the same as above. An alternate route used
o prepare 13 and 15 was alkylation of the ester 29 fol-
owed by simultaneous Dimroth rearrangement and
minolysis of the methyl ester group and then acidic
eprotection.
2AAR Modeling and Site-Directed Mutagenesis
olecular modeling was used to make predictions of
hich complementary groups on the ligand and recep-
or may interact. The human A2AAR was modeled as
escribed, based on a rhodopsin template [26], and re-
resentative adenosine derivatives were docked in a
utative binding site [10]. Modeling has predicted the
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239Table 1. Binding Affinity of Ligands at WT and Mutant Human A2AARs Expressed in COS7 Cells
Ki (nM)
Compound Constructb
WT T88D Q89D N181D
3c 21.4 ± 8.7 >10,000 1.5 ± 0.4 9.3d
4c 0.84 ± 0.22 0.91 ± 0.09 0.35 ± 0.12 0.45d
5 >100,000 >100,000 >10,000 >10,000
6 4,510 ± 150 5,680 ± 980 773 ± 129 1,140 ± 180
7 11,000 ± 2,900 32,800 ± 11,400 16.4 ± 2.1 1,180 ± 480
1 46,100 ± 4,200a 4,400 ± 1,600a 3,600 ± 1,000a 493 ± 138
8 74,200 ± 24,800 57,600 ± 11,700 10,800 ± 1,500 4,140 ± 160
9 >100,000 >100,000 55,200 ± 8,400 48,100 ± 4,400
10 >100,000 >100,000 124,000 ± 36,000 >100,000
11 2,110 ± 260 3,870 ± 1210 41.7 ± 7.3 13,300 ± 1,600
12 >100,000 >10,000 545 ± 145 >100,000
13 2,590 ± 140 >100,000 246 ± 36 3,470 ± 430
14 >100,000 >100,000 443 ± 16 320 ± 52
15 >10,000 >100,000 444 ± 127 6090 ± 380
17 >10,000c >100,000 >10,000c >100,000
18 >100,000 >100,000 >100,000 >100,000
19 >100,000 >100,000 >100,000 >100,000
Compound 4 is the only nonnucleoside (nonselective antagonist CGS15943) included. Membranes from COS-7 cells transfected with WT or
mutant A2AAR cDNA were incubated with 2.0 nM [3H]ZM241385 in duplicate, together with increasing concentrations of the competing
compounds, in a final volume of 0.2 ml Tris-HCl buffer (50 mM, [pH 7.4]) at 25°C for 120 min. The Ki values are expressed as mean ± standard
error from three independent experiments, unless noted. The Kd values determined for saturation of binding of [3H]ZM241385 were (nM, mean ±
SEM): WT, 2.4 ± 0.7; T88D, 4.2 ± 0.5; Q89D, 4.6 ± 1.8; and N181D, 4.1 ± 0.4.
a From Kim et al. [10].
b Binding affinities at the N253D-A2AAR could not be determined, since this construct lost the ability to bind either agonist or antagonist
radioligand.
c Ki values of the nonselective agonist NECA 3 and antagonist CGS15943 4 bound at the T88E-A2AAR were >10,000 and 0.67 ± 0.17 nM,
respectively. Ki values for 17 of 63 and 17 µM determined at WT and Q89D-A2AARs, respectively (n = 1).
d n = 1.proximity of the amino groups of the adenosine analogs
to specific residues of the human A2AAR. The deriva-
tives that possess a positively charged nitrogen atom
linked through the N6-position (5, 6) are hypothesized
to interact with an anionic group placed in the vicinity ofN253. The derivatives that bear an amino group linked
through the 5# position (7–10, 14) are hypothesized to
interact with an anionic group placed in the vicinity of
T88 or N181. The two-carbon homolog in this series 1
was already demonstrated to have enhanced affinity at
Chemistry & Biology
240Figure 2. Synthesis of N6-Derivatized Adeno-
sine Analogs 5 and 6
Reagents: (A) (i) ethylendiamine, rt., 24 hr; (ii)
1 N HCl, MeOH-H2O (1:1), 55°C, 36 hr, 65%.
(B). (i) 2,2-dimethoxypropane, p-TsOH, ace-
tone, 4 hr, 85%; (ii) TBDMS-Cl, imidazole,
pyridine, 1 hr, 83%; (iii) guanidine solution,
DABCO, 3 hr, 70%; (iv) Bu4N+F-, THF, 1hr,
95%; (v) KMnO4, KOH, H2O, 5 hr, 50%; (vi)
H2SO4, 3 hr, 60°C, 84%; (vii) (a) ClCOOEt,
N,N- i-Pr2NEt, DMF, 0°C; (b) EtNH2 in MeOH,
0°C 1 hr, RT 24 hr, 50%.the T88D mutant A2AAR [10]. The derivatives that bear a
Tan amino group linked through the 2 position are hy-
pothesized to interact with an anionic group placed in a
bthe vicinity of Q89 or N181.
Several new mutant human A2AARs were prepared to k
ttest these hypotheses. The N181D- and N253D-A2AARs
were constructed for the present study and expressed w
Ain COS-7 cells. The T88D and Q89D-A2AARs prepared
previously [10, 27] were utilized to examine the new li- c
ngand structures. A summary of the affinities of 5#-N-ethyl-
uronamidoadenosine (NECA) 3 and 5-amino-9-chloro-2- s
d(2-furyl)-1,2,4-triazolo[1,5-c]quinazoline (CGS15943) 4,
standard nonselective AR agonist and antagonist, w
mrespectively, at the mutant receptors transiently ex-
pressed in COS-7 cells is provided in Table 1. The affin- g
aity of NECA 3 was greatly reduced at both T88 mutant
ARs. The N253D-A2AAR lost the ability to bind either p
aagonist or antagonist radioligand with high affinity. The
other mutant receptors, nevertheless, could be char- A
acterized using the conventional A2AAR antagonist
radioligand [3H]ZM241,385 (4-2-[7-amino-2-(2-furyl)- 1
t1,2,4-triazolo[1,5-a] [1, 3, 5]triazin-5-yl-amino]ethylphe-
nol) [28]. A
N
Interaction of Adenosine Derivatives
with the WT ARs I
wInitially, the adenosine derivatives were examined in as-
says at the native ARs. Binding assays were carried S
nout at recombinant human A1, A2A, and A3ARs stably
expressed in CHO cells (Table 2). In a functional assay p
gat the WT A2AAR consisting of activation of adenylate
cyclase [29], the adenosine derivatives were all ago- s
wnists. The assay of cAMP was also used to examine
activation of the Gs-coupled human A2BAR stably ex- t
hpressed in CHO cells. Nucleosides that were moderately
selective in binding to the A1 AR were the 2-hydroxy- o
tethyluronamide 11 and the N6-aminoethyl derivative 5,
with Ki values of 12.8 and 775 nM, respectively. The c
sN6-guanidino derivative of NECA 6 was somewhat se-
lective for the A1 and A3ARs and displayed strikingly
6high affinity at the A AR, with a K value of 5 nM, and3 it the A2BAR, with a 3-fold enhancement over NECA 3.
he hydrazide 12 was somewhat selective for the A3AR,
nd the N-ethyluronamide 13 had mixed selectivity for
oth A1 and A3ARs. Within the series of 5#-N-aminoal-
yluronamides 1, 8–10, the highest affinity at all sub-
ypes was observed for the two-carbon homolog 1,
hich displayed an order of affinity of A1 > A2A, A2B >>
3. The isoelectronic 2-hydroxyethyl analog 11 was of
onsiderably higher affinity/potency than 1 at all four
ative AR subtypes. Thus, consistent with previous ob-
ervations, amine functionalization in the ribose region
isfavored binding to the native ARs. The hydrazide 7
as similar in affinity to 1 at A1, A2A, and A2BARs and
ore potent at the A3AR. Appending a 2-methylbenzyl
roup at the N6 position of 1 to provide 14 reduced
ffinity/potency at all four native AR subtypes. A com-
arison of the affinities of NECA 3 and its hydroxylated
nalog 11 showed a dramatic loss of affinity at A2A and
3ARs as a result of the 2-hydroxyl group.
The 2-position derivatives of N6-methyladenosine
7–19 recently reported by us [12] tended to be selec-
ive for the human A3AR and nearly inactive at A2A and
2BARs. This characteristic was also noted for other
6-methyladenosine derivatives [12, 30].
nteraction of Adenosine Derivatives
ith the Mutant A2AARs
elective affinity enhancement was observed for some
ucleoside derivatives at A2AAR mutant receptors ex-
ressed in COS-7 cells (Table 1). Amine-containing
roups placed at the 2 position (17–19) on the nucleo-
ides did not enhance the binding to mutant receptors,
hile the addition of the amine-containing groups to
he N6 position in 5 and 6 caused a slight affinity en-
ancement. For example, a small enhancement was
bserved at the Q89D-A2AAR in comparison to WT for
he 6-guanidino derivative 6 (6-fold). However, modifi-
ation of the 5# position provided many examples of
electively enhanced affinity at the mutant receptors.
A 5#-hydrazide analog (compound 7) displayed a
70-fold enhancement of affinity at the transiently ex-
Selectively Activated Adenosine Neoceptors
241Figure 3. Synthetic Routes to Various Mono-
and Disubstituted Adenosine-5#-Uronamide
Derivatives
(A) Synthesis of adenosine-5#-uronamide an-
alogs 1 and 8–10.
(B) Synthesis of N6-(2-methylbenzyl)adeno-
sine-5#-uronamide analogs 12–15. Reagents:
(i) CrO3, AcOH, 18%; (ii) TMSCHN2, MeOH,
88%; (iii) RNH2, DMF, 60°C; (iv) 1N HCl
MeOH-H2O (1:1) 55°C, 2 d; (v) RP-SiO2 C18,
for 7, Amberlite CG-50, for 11 and 12–15;
(vi) Boc-NH(CH2)nNH2, iPr2NEt, DMF, 60°C,
54%–97%; (vii) Amberlite CG-50, 13%–67%;
(viii) 2-MeBnBr; (ix) ethylamine or ethanol-
amine, MeOH, heat, Dimroth rearrangement
and aminolysis of ester.
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242Table 2. Affinity or Potency of Various Adenosine Derivatives at Human Adenosine Receptors
hA3 Binding
Compounda hA1 Binding Ki(nM)b hA2A Binding Ki(nM)c hA2A Activation %c hA2B Activation EC50d Ki(nM)c
3 6.8 ± 2.4 2.2 ± 0.6 100 140 ± 19 (n = 4) 16.0 ± 5.4
5 775 ± 235 >100,000 32.9 ± 2.0 >10,000 24,600 ± 8,200
6 7.0 ± 1.0 628 ± 39 102 ± 4 54.5 ± 13.3 5.1 ± 1.3
7 171 ± 15 2,230 ± 330 92.2 ± 1.0 12,000 ± 4200 378 ± 33
1 245 ± 48 3,120 ± 370 90.3 ± 1.4 15,600 ± 2,800 >100,000
8 >100,000 >10,000 51.0 ± 7.6 >10,000 >10,000
9 >100,000 >100,000 11.6 ± 4.6 >10,000 >10,000
10 >100,000 >100,000 0 >10,000 >100,000
11 12.8 ± 3.1 505 ± 30 84.5 ± 3.4 942 ± 38 9450 ± 1760
12 >10,000 >10,000 78.9 ± 4.5 >100,000 394 ± 74
13 106 ± 30 5430d 108 ± 3 >1000 78.8 ± 25.5
14 >10,000 55,900 ± 4,600 91.4 ± 5.2 >1,000 >10,000
15 368 ± 147 >10,000 102 ± 2 3,720d 1,640 ± 400
16 39.3 ± 8.3 764 ± 105 112 ± 6 ND 47.2 ± 10.8
17 484 ± 22 >10,000 93.3 ± 5.5 >10,000 39.0 ± 2.4
18 >10,000 >10,000 42.2 ± 1.3 >10,000 719 ± 37
19 >10,000 >10,000 2 >10,000 2,730 ± 268
n = 3, unless noted. ND, not determined.
a Structures shown in Table 1. 1, MRS3366; 3, NECA; 6, MRS3218; 7, MRS3412; 11, MRS3407; 14, MRS3417.
b Binding experiments carried out for various subtypes of human recombinant adenosine receptors stably expressed in mammalian cells
using the following radioligands (concentration): hA1 (CHO cells), [3H]R-PIA (2.0 nM); hA2A (HEK-293 cells), [3H]CGS21680 (15 nM); hA3 (CHO
cells), [125I]I-AB-MECA (0.5 nM).
c At hA2A and hA2B receptors expressed in CHO cells, cAMP was measured. For hA2A receptors, values are expressed as percent stimulation
of cyclic AMP production at 100 µM (value for NECA is 100%).
d n = 1.pressed Q89D-A2AAR compared to the WT receptor f
8and no enhancement at the T88D-A2AAR (Figure 4A). In
contrast, the affinity at the T88D-A2AAR of compound Q
(1, which has a 5# chain elongated by two methylene
units, was increased by w10-fold over the WT. The m
Q5#-(2-aminoethyl)uronamide derivative 1 [10] was pre-
ferred to its longer homologs 8–10 in binding enhance- T
fment at the T88D- and N181D-A2AARs. Thus, the length
of the 5# chain might be a key factor for enhancement. (
The affinity of compound 1 was also enhanced by 13- In order to characterize the functional properties of
Figure 4. Pharmacological Characterization
of Two Neoagonists Indicates Selective In-
teraction with Neoceptors Derived from the
A2AAR
Binding (A and B) and functional (C and D)
effects of two adenosine derivatives, the hy-
drazide derivative 7 (A) and the N6-(2-methyl-
benzyl)-5#-aminoethyluronamide derivative 14
(B) at WT (■) and mutant A2AARs (T88D [:],
N181D [%], and Q89D [;]) transiently ex-
pressed in COS-7 cells. In the binding experi-
ments, cell membranes (10–20 g protein)
were incubated with the radiolabeled antag-
onist [3H]ZM241385 (2.0 nM) in duplicate, to-
gether with increasing concentrations of the
competing nucleoside, in a final volume of
0.4 ml Tris-HCl buffer (50 mM, pH 7.4) at
25°C for 120 min. Results were from a repre-
sentative experiment performed in duplicate.
The Ki values listed in Table 1 were from at
least three separate experiments. In the
functional experiments, cells expressing WT
or mutant receptors were then treated with
agonist 7 (C) or 14 (D) in the presence of rolipram (10 M) and adenosine deaminase (3 units/ml) and incubated at 37°C for 1 hr. cAMP
accumulation was determined using a competitive protein binding method [29]. The EC50 values (n = 3) determined for stimulation of cAMP
formation were (nM, mean ± SEM): WT, 826 ± 138; T88D, 2970 ± 980; Q89D, 5.1 ± 0.8; N181D, 120 ± 22 for 7; and WT, 5800 ± 1230; T88D,
12,600 ± 3200; Q89D, 58 ± 12; N181D, 52 ± 6 for 14.old at the Q89D mutant receptor. The higher homolog
displayed a less pronounced enhancement at the
89D-A2AAR compared with 1. Combination of the 5#-
2-aminoethyl)uronamide modification with the N6-(2-
ethylbenzyl) group in 14 provided enhancement at the
89D- and N181D-A2AARs (Figure 4B) but not at the
88D-A2AAR. At the N181D-A2AAR, enhancement of af-
inity (fold over WT) was observed for 1 (94), 6 (4), 8
16), 14 (>300), and 15 (>10).
Selectively Activated Adenosine Neoceptors
243neoceptor-neoligand pairs, effects on adenylate cy-
clase by selected neoligands were studied in CHO cells
transiently expressing WT and mutant A2AARs (T88D,
Q89D, and N181D). Concentration-response curves for
cAMP accumulation at the WT and mutant A2AARs (Fig-
ures 4C and 4D) were generated for two neoligands, 7
and 14. These nucleosides were demonstrated to be
full agonists as compared with the known agonist
NECA, and the potency orders were commensurate
with the binding affinities. The potency compared to the
WT A2AAR of the 5#-hydrazide analog 7 was 162-fold
enhanced at the Q89D-A2AAR (EC50 5.1 ± 0.8 nM), and
that of the aminoethyl derivative 14 was 112-fold en-
hanced at the N181D-A2AAR (EC50 52 ± 6 nM). Both
nucleoside derivatives were less potent in activating
the T88D mutant receptor than the WT receptor.
The Docking Result of Amine Derivatives
with the Mutant A2AARs
Construction of molecular models of the WT and T88D-
A2AARs and the docking of 1 have been described [10].
A similar approach was adopted to model interactions
with the Q89D- and N181D-A2AARs. The modeling of
the N181D/1 complex indicated a direct contact of the
ligand with the newly added carboxylate group. At the
Q89D-A2AAR, most of the nucleosides examined dis-
played enhanced affinity, and thus, these enhancements
did not provide insights into specific interactions. Con-
sistent with this observation, the modeling of the
Q89D/7 complex did not indicate a direct contact with
the carboxylate group.
For the side-chain refinement of Q89D- and N181D-
A2AARs, after the mutation of each side chain the re-
ceptor models were optimized through a molecular dy-
namics (MD) procedure. In the previous model of the
T88D-A2AAR [10], the trans-rotamer of the χ1 angle of
this side chain was preferred over the gauche+ confor-
mation shown in the WT receptor because of the forma-
tion of H bonding of the new carboxylate group with
the neighboring hydrophilic residue, N181 (5.42). This
local conformational change toward the upper portion
of TM5 was consistent with the binding profile of this
mutant receptor; the extended 5#-aminoethyluronam-
ide was enhanced in binding affinity, while 5#-amino-
5#-deoxyadenosine 2 displayed poor binding affinity,
similar to its binding affinity at the WT A2AAR. The MD
result of the Q89D-A2AAR displayed the same χ1 angle
as the WT receptor, i.e., gauche+. The side chain of Q89
formed a H bond with the carbonyl oxygen atom of
C185 (5.46) in the resting WT receptor structure. How-
ever, in the Q89D-A2AAR, the carboxylate group did not
display any H bonding with the surrounding residues.
In the N181D-A2AAR, D181 (5.42) showed additional H
bonding with the imidazole ring of H250 (6.52), keeping
the same trans χ1 angle of N181 (5.42) in WT receptor
without H bonding to H250 (6.52). Thus, both human
A2A Q89D- and N181D-A2AARs showed the same pref-
erence of χ1 angle compared with the WT but with dif-
ferent intramolecular H-bonding character. The differ-
ences included the loss of H bonding with Q89D and
the formation of H bonding in N181D-A2AAR.
In the case of the human A2AAR complex with the
nonselective agonist NECA 3 [10], H bonds formed be-tween the exocyclic amine and the side chain amide
NH of N253 (6.55), between the purine N1 atom and the
side chain of N181 (5.42), and between the purine N3
atom and the side chain of T88 (3.36). The 3#-OH group
H bonded with the δ1 NH of H278 (7.43). The 5#-amide
NH also formed a H bond with T88 (3.36), and the 5#-
carbonyl group displayed H bonding with the hydroxyl
group of S277 (7.42). NECA, which bound to the Q89D-
and N181D-A2AARs, displayed similar binding orienta-
tions with respect to the same residues in proximity to
NECA 3 bound in the WT human A2AAR.
In the Q89D-A2AAR/NECA 3 complex, which did not
show direct interaction of the ligand with D89 (3.37),
there were additional H bonds of the N6-amine with the
side chain of N181 and of the ribose ring oxygen with
the hydroxyl group of T88 (3.36). This was consistent
with a 14-fold increase of binding affinity for NECA. The
docking result of the human A2A N181D-A2AAR/NECA 3
complex displayed alternative H bonding between the
exocyclic amine and the side chain of D181 (5.42). The
nonbonding energy components of the three NECA 3
complexes with the WT, Q89D-, and N181D-A2AARs in-
dicated a correlation between the experimental binding
affinity (−logKi) and the calculated nonbonding energy
of complex (r2 value was 0.99). This implied an inverse
relationship between the nonbonding van der Waals
and the electrostatic energy.
For the docking studies of neoceptor and neoligand,
the thermodynamically stable conformations of several
ligands were calculated. Conformational searching was
performed using MOPAC PM3 calculations. The result-
ing low-energy conformers of 1, 7, 8, 9, 10, and 11 dis-
played intramolecular hydrogen bonding of the terminal
ammonium or the hydroxyl group with the 5#-carbonyl
oxygen atom. In the case of longer aminoalkyl homo-
logs 8, 9, and 10, the interaction of the terminal ammo-
nium group and the N7 atom in the adenine ring was
indicated, due to the length of the 5# substituent.
The lowest-energy conformer of 1 was superimposed
onto the N181D-A2AAR using an atom-by-atom fitting
from the human A2AAR/NECA 3 complex. The overlay
indicated that the 5#-ammonium group of 1 was unable
to interact with the side chain of D181 (5.42). However,
a different binding mode that was more energetically
favorable than in the A2AAR/NECA 3 complex was sug-
gested using the automatic docking program. This
mode featured a direct interaction of the terminal posi-
tively charged ammonium ion and the negatively
charged carboxylate ion of D181 (5.42). Figure 5A
shows the docking result of the N181D-A2AAR/1 com-
plex. The exocyclic amino group interacted with the hy-
droxyl group of S277 (7.43) and the imidazole ring of
H278 (7.43) through H bonding. The 3#-OH group
formed a H bond with the backbone carbonyl group of
T88 (3.36). In the binding site of the 5# substituent, the
NH group formed a H bond with the imidazole ring of
H250 (6.52). The terminal NH3+ group interacted with
the negatively charged side chain of D181 (5.42)
through a salt bridge (3.0 Å between the N of the ter-
minal NH3+ in 1 and the O of the carboxylate ion) as
well as through H bonding (2.1–2.8 Å). In addition, there
were additional H bonds (2.5–2.7 Å) with the backbone
carbonyl of D181 (5.42) and C185 (5.46). However, in
the complex of 2-hydroxyethyluronamideadenosine 11,
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WA2AAR
cThe binding site of (A) the N181D-A2AAR/1 and (B) the Q89D-
A2AAR/7 complex. All ligands are displayed as ball-and-stick mod- p
els in the atom-by-atom color, and the side chains of human A2AAR s
are shown as stick models. The H bonding between ligand and the t
mutant receptor is displayed in yellow. The A2AAR is represented s
by a tube model with a different color for each TM domain (TM3 in
Tyellow, TM5 in green, TM6 in cyan, and TM7 in purple).
c
A
tthere was only H bonding (2.3 Å) with the side chain of
D181 (5.42), consistent with its 27-fold decrease of the N
tbinding affinity compared with 2-aminoethyluronam-
ideadenosine 1. In the case of the docking result of 8, m
having one more methylene unit, the complex still
showed a salt bridge (2.8 and 3.3 Å between the N of A
tthe terminal NH3+ in 7 and the O of the carboxylate ion).
The H bonds with the side chain of D181 of length 2.2 (
sand 2.5 Å were weakened, and H bonding with the
backbone carbonyl groups of D181 and C185, detected p
2in the docking complex of 1, was absent. Correlating
with its experimental data, the complex of 9 displayed c
just one H bond (2.7 Å) with D181 (5.42), and the com-lex of 10 showed a distortion of the α-helical structure
f TM5. The r2 value of correlation between the binding
ffinity and the nonbonding energy of the complex was
.96. Compound 14 docked with the same binding
ode as compound 8, displaying additional bonding at
he N6 position in upper TM7. In Figure 5A, the terminal
H3+ group reached the side chain of Q89 (3.37) due to
he flexibility of 5#-terminal group, possibly explaining
he increase of binding affinity at both Q89D- and
181D-A2AARs.
In the docking complex of the Q89D-A2AAR with 1, 7,
nd 11, energetically favorable binding modes followed
similar binding geometry of the ribose ring to that
hown in the A2AAR/NECA 3 complex. In that complex,
here was no interaction between the 5#-terminal group
nd the side chain of D89 (3.37). As illustrated in Figure
B, the exocyclic amino group, the purine N1 atom, and
he 5#-NH group of 7 interacted through H bonds with
he N253 (6.55), N181 (542), and the T88 (3.36), respec-
ively, as shown by the A2AAR/NECA 3 complex. The
#-OH group instead of the 3#-OH group formed a H
ond with the imidazole ring of H278 (7.43). Com-
ounds 1 and 11 showed intramolecular H bonding of
he 5#-terminal NH3+ or the hydroxyl group with the 5#-
arbonyl oxygen in the bound conformation as well as
n the unbound state. Because of the limitation of space
t the 5# binding site, a bulkier group decreased the
inding affinity to the Q89D-A2AAR. The binding modes
f several 5#-ammonium analogs with various lengths
f the methylene chain in the N181D-A2AAR were dif-
erent from those in the Q89D-A2AAR. This was consis-
ent with two different modes observed for binding of
#- and 5#-amino analogs in the T88D-A2AAR [10]. Thus,
he results of molecular modeling explained the experi-
ental data for some neoligands.
The loss of binding affinity at the WT and mutant
2AARs of 2-position derivatives, 17–19, seems to be
haracteristic of N6-methyl adenosine derivatives, which
end to have increased selectivity for the hA3 AR [12].
iscussion
e have used both rational and empirical design pro-
esses to identify pairs of neoceptor-neoligand that are
harmacologically orthogonal with respect to the native
pecies. In principle, it could be possible to redesign
he binding site for recognition of a radically different
tructure, i.e., use the parent receptor as template only.
he T88D-A2AAR is truly a “neoceptor,” since its re-
ognition profile is distinct from that of the parent
2AAR. Only compound 1 was enhanced in affinity at
his construct in comparison to the WT A2AAR. At the
181D-A2AAR, the degree of enhancement was higher
han at the T88D-A2AAR. Compounds 1 and 14 were
ost highly enhanced in affinity at the N181D-A2AAR.
Orthogonality of selective interaction with mutant
2AARs has been achieved for two nucleoside deriva-
ives, 7 and 14. The selectivity ratios for compound 7
MRS3412) in binding to the mutant Q89D-A2AAR (tran-
iently expressed) in comparison to the stably ex-
ressed WT A1-, A2A-, and A3ARs were 10, 136, and
3-fold, respectively. Comparable selectivity ratios for
ompound 14 (MRS3417) in binding to the mutantN181D-A2AAR (transiently expressed) were >31, 175,
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245and >31-fold, respectively. The T88D, Q89D, and N181D
mutations within the putative ribose binding region of
the A2AAR agonist binding site [10] did not impair sig-
naling properties of the receptor. In the functional as-
says of adenylate cyclase stimulation, compound 7 act-
ing at the Q89D-A2AAR was more potent than 14 acting
at the N181D-A2AAR, consistent with the binding re-
sults. Potency at the A2BAR was very weak for both
agonists, so the presence of this subtype will not likely
be a complicating factor in envisioned in vivo use of
these nucleosides.
We have used molecular modeling to provide hypoth-
eses for the selective enhancement of affinity observed
for certain pairs of nucleoside and mutated receptor.
At the T88D-A2AAR, most of the nucleosides examined
bound weakly or not at all, and therefore the dramatic
gain of affinity of 1 has been interpreted to imply a di-
rect contact between the ligand and the D88 side chain.
In contrast, at the Q89D-A2AAR, NECA 3 and most other
agonists also displayed enhanced affinity (Table 1). The
enhancements of the adenosine derivatives could not
readily be ascribed to a specific electrostatic or H-bond-
ing interaction with the newly introduced carboxylic acid
group. This is supported by the observation that a vari-
ety of single amino acid replacements of Q89 enhanced
agonist affinity, regardless of the chemical nature of the
side chain. Thus, a specific conformational hypothesis
to explain the 670-fold affinity enhancement of 7 was
lacking. However, at the N181D-A2AAR, the affinity of
NECA was only minimally increased. Thus, we have
used molecular modeling to propose a direct interac-
tion between 7 and the D88 side chain.
In addition to introducing novel molecules that may
now be explored pharmacologically in the context of
therapeutics, at the same time the neoceptor approach
has validated key contact regions in the receptor mod-
els. We interpret the results in the context of formation
of new electrostatic and other polar interactions to en-
hance affinity, i.e., a gain of function. Since the se-
quence of rhodopsin has only <20% homology to the
AR sequences, this is an important aspect of the study.
The present study also emphasizes the limitations of
the current GPCR modeling, since several predicted in-
teractions (e.g., enhancement of the affinity of 2-amino
derivatives at the Q89D-A2AAR) were not explicable.
There are several limitations to the neoceptor approach
as a rational approach: (1) the homology modeling
method is imprecise (the limitations of using a rhodop-
sin template, especially for modeling agonist binding
have been discussed [10]), and (2) the side chains may
rearrange upon mutation to lose predictability of in-
teraction with the ligand. It is evident that electrostatic
interactions, e.g., from an amine-bearing ligand and
carboxylate-modified protein, are not the only basis on
which a selective enhancement may be achieved. Other
principles of enhancement might be based on more
extensive H-bonding ability or on hydrophobic interac-
tions.
In the projected therapeutic application of neocep-
tors, i.e., by introducing the gene for the mutant recep-
tor using an organ- or tissue-targeted vector for in vivo
delivery [9, 31–33], the protective role of native ARs
would not be affected. Ideally, the native ligand and
neoligand would exclusively activate their respective
receptors. This orthogonal approach is predicated onthe neoceptor interacting with the necessary second
messenger systems. Thus, the addition of the neocep-
tor to the functioning of the tissue would be a parallel
process, to be invoked only as needed clinically, and
not to interfere with critical functions of endogenous
adenosine. Therefore, the drug action would be site
specific and would avoid side effects of activation of
subtypes of native ARs.
Significance
GPCRs constitute the target mechanism of roughly
half of the pharmaceutical substances in commercial
use. The therapeutic use of agonists of GPCRs is
prone to side effects, due to frequently widespread
distribution of a given receptor subtype. For example,
in the adenosine system, no potent and selective ago-
nists of any of the four receptor subtypes have yet
been approved for therapeutic use, in spite of the
thousands of agonists synthesized and selectivity
achieved. The A2AAR in the immune system is in-
volved in suppressing prolonged inflammatory re-
sponses. It also has several cardiovascular actions,
such as vasodilation [1, 2], which may be considered
side effects in this context. One means of overcoming
side effects of the A2A receptor and of other GPCRs
is to establish a new basis for selectivity of uniquely
tailored small molecular agonists for engineered re-
ceptors, which could potentially be delivered by ge-
netic means to a target organ.
The neoceptor approach to engineering GPCRs for
unique activation is based on the use of molecular
modeling to identify and later alter the recognition el-
ements of a GPCR binding site, such that only neoli-
gands will activate the mutant receptor [9, 10]. The
present study initially attempted to enhance A2A re-
ceptor affinity in the orthogonal pairs based on elec-
trostatic attraction of a cationic nucleoside agonist
and anionic TM of the receptor protein. This study
revealed additional possibilities not predicted using
receptor modeling, such as enhanced H-bonding abil-
ity. Selective enhancements of several hundred-fold
were achieved. Also, other combinations not explored
here are possible, e.g., placing a negative charge on
the ligand and a positively charged side chain on
the receptor.
Given the identification of unique neoligand/necep-
tor pairs, it is now appropriate to perform more exten-
sive pharmacological studies, including functional
cell systems and transgenic mice.
Experimental Procedures
Human A2AAR cDNA (expression vector pSVL-A2A) was kindly pro-
vided by Dr. M. Jacobson (Merck Research Labs, West Point, PA).
Oligonucleotides used were synthesized by Bioserve Biotechnol-
ogies (Laurel, MD). [3H]ZM241385 (4-(2-[7-amino-2-(2-furyl)1,2,4]tri-
azolo [2,3a] [1,3,5]triazin-5-ylamino]ethyl)phenol, 17 Ci/mmol) was
from Tocris Cookson Ltd. (Bristol, United Kingdom). Adenosine de-
aminase, CGS15943, and NECA were obtained from Sigma (Saint
Louis, MO). All other compounds were obtained from standard
commercial sources and were of analytical grade. Detailed meth-
ods used for chemical synthesis [22–25] and along with the coordi-
nates of the hypothetical neoceptor-neoligand complex shown in
Figure 5A, derived using molecular modeling [34–38], are provided
in the Supplemental Data.
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tThe protocols used were as described in the QuikChange Site-
directed Mutagenesis Kit (Stratagene, La Jolla, CA). Mutations
bwere confirmed by DNA sequencing. Lipofectamine 2000 (Invitro-
gen Life Technologies) was used for transfection of WT and mutant r
sreceptor cDNA to COS-7 cells.
c
pMembrane Preparation
aAfter 48 hr of transfection, COS-7 cells were harvested and homog-
oenized with a Polytron homogenizer. The homogenates were centri-
1fuged at 20,000 × g for 20 min, and the resulting pellet was resus-
[pended in the 50 mM Tris-HCl buffer (pH 7.4) and stored at –80°C
ain aliquots. The protein concentration was determined by using the
wmethod of Bradford [39].
t
s
Radioligand Binding and Functional cAMP Assay
The procedures of [3H]ZM241385 binding to WT and mutant human A
A2AARs was as previously described [28]. For saturation experi- t
ments, membranes (20–40 g of protein) were incubated with f
increasing concentrations (0.5–16 nM) of [3H]ZM241385 in dupli- n
cate, in a final volume of 0.4 ml of Tris-HCl buffer (50 mM, pH 7.4 f
at 20°), at 25° for 120 min. Nonspecific binding was defined as the t
binding retained on the filter and membranes in the presence of 1 f
M CGS15943. For competition experiments, the membranes (20 w
g of protein) were incubated with 2.0 nM [3H]ZM241385 in dupli- t
cate, with increasing concentrations of the competing compounds, H
in a final volume of 0.2 ml Tris-HCl buffer (50 mM, pH 7.4) at 25°C g
for 120 min. Binding reactions were terminated by filtration through a
Whatman GF/B glass-fiber filters under reduced pressure with an s
MT-24 cell harvester (Brandel, Gaithersburg, MD). The filters were i
washed three times with ice-cold buffer and placed in scintillation i
vials containing 5 ml scintillation fluid, and bound radioactivity was F
determined by using a liquid scintillation counter. w
Intracellular cyclic AMP levels were measured with a competitive F
protein binding method [29]. Briefly, CHO cells expressing WT and f
mutant ARs were harvested by trypsinization. After resuspension g
in the medium, cells were plated in 24-well plates in 0.5 ml medium/
well. After 24 hr, the medium was removed and cells were washed
three times with 1 ml/well of DMEM, containing 50 mM N-2- S
hydroxyethylpiperazine-N#-2-ethanesulfonic acid (pH 7.4). Cells S
were then treated with agonists and/or test compounds in the pres- w
ence of rolipram (10 M) and adenosine deaminase (3 units/mL)
and incubated at 37°C for 1 hr. The reaction was terminated upon
removal of the medium, and the cells were lysed with 200 l/well A
of 0.1 M ice-cold HCl. The cell lysate was resuspended and stored
at –20°C. For determination of cyclic AMP production, protein ki- W
nase A (PKA) was incubated with [3H]cyclic AMP (2 nM) in K2HPO4/ t
EDTA buffer (K2HPO4, 150 mM; EDTA, 10 mM), 20 µl of the cell i
lysate, and 30 µl 0.1 M HCl. Bound radioactivity, separated by rapid T
filtration through Whatman GF/C filters under reduced pressure s
and washed once with cold buffer, was measured by liquid scintilla- f
tion spectrometry.
RStatistical Analysis
R
Binding and functional parameters were estimated with GraphPad
A
Prism software (GraphPad, San Diego, CA). IC50 values obtained P
from competition curves were converted to Ki values by using the
Cheng-Prusoff equation [40]. Data were expressed as mean ± stan-
Rdard error.
Molecular Modeling
All calculations were performed using the SYBYL program [34] ver-
sion 6.9 on a Silicon Graphics Octane workstation (300 MHz MIPS
R12000 [IP30] processor). All ligand structures were derived using
the “Sketch Molecule” and were performed by random search for
all rotatable bonds. The options of the random search consisted of
3000 iterations, 3 kcal energy cutoffs, and chirality checking. MMFF
force field [35] and charge were applied using distance-dependent
dielectric constants and the conjugate gradient method until the
gradient reached 0.05 kcal/mol/Å. After clustering the low energy
conformers from the result of the conformational search, the repre-
sentative conformers from all groups were reoptimized by semi-mpirical molecular orbital calculations using the PM3 method in
he MOPAC 6.0 package [36].
The previously published human A2AAR model (PDB code: 1upe)
uilt by homology modeling [10] from the X-ray structure of bovine
hodopsin with 2.8 Å resolution [26] was used for the docking
tudy. For the side-chain refinement of the Q89D and N181D neo-
eptors, the optimized structures were then used as the starting
oint for subsequent 50 ps MD, during which the protein backbone
toms in the secondary structures were constrained. The options
f MD at 300 K with a 0.2 ps coupling constant were a time step of
fs and a nonbonded update every 25 fs. The SHAKE algorithm
37] was employed to fix the lengths of bonds with hydrogen
toms. The average structure from the last 10 ps trajectory of MD
as optimized with backbone constraints in the secondary struc-
ure and then the unconstrained structure was minimized as de-
cribed above.
Compounds 1, 7, 8, 9, 10, and 11 were docked within the human
2AAR and neoceptors. Flexible docking was facilitated through
he FlexiDock utility in the Biopolymer module of SYBYL 6.9. During
lexible docking, the rotatable bonds in the 5#-terminal group of the
eoligand and the side chains of acidic residues were defined with
lexible bonds. After the hydrogen atoms were added to the recep-
or, atomic charges were recalculated by using Kollman all-atom
or the protein and Gasteiger-Hückel for the ligand. H-bonding sites
ere identified for acidic residues of neoceptor and for the posi-
ively charged groups of the neoligands that were able to act as an
-bond donor or acceptor. The lowest energy conformer of neoli-
and was variously prepositioned in the putative binding cavity as
starting point for FlexiDock. Default FlexiDock parameters were
et at 3000 generation for genetic algorithms. To increase the bind-
ng interaction, the torsion angles of the side chains that directly
nteracted within 5 Å of the ligands, according to the results of
lexiDock, were manually adjusted. The atom types of all ligands
ere manually assigned with an Amber all-atom force field [38].
inally, the complex structure was minimized by using an Amber
orce field with a fixed dielectric constant (4.0), until the conjugate
radient reached 0.1 kcal , mol–1 , Å–1.
upplemental Data
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ww.chembiol.com/cgi/content/full/12/2/237/DC1/.
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